Patent ID: 9534202
Date: 2017-01-03
CPC Classifications: A61P,C12N

Claim:
1. A method for treating progressive decline in heart muscle function due to myocardial ischemia, which comprises (a) determining eligibility of the subject by clinically evaluating the heart muscle function; (b) administering parenterally to the subject through a catheter on a first infusion date a sterile pharmaceutical composition comprising a therapeutic amount of a chemotactic hematopoietic stem cell product comprising: the composition being characterized as having the following properties for at least 24 hours following acquisition of the mononuclear cells when tested in vitro after passage through the catheter: (1) at least 70% of the cells in the composition are CD34+ cells, (2) the subpopulation of CD34+/CXCR-4+ cells have CXCR-4-mediated chemotactic activity move in response to SDF-1, (3) at least 70% of the cells in the composition are viable, and (4) can form hematopoietic colonies in vitro; wherein the therapeutic amount of the chemotactic hematopoietic stem cell product comprises at least 10 million isolated CD34+ cells comprising at least 0.5×10 (c) repeating steps (a) through (b) on at least one or more infusion dates during the subject's lifetime; thereby treating the progressive decline in heart muscle function due to myocardial ischemia by: